Catalina Capital Group LLC Acquires Shares of 955 Cencora, Inc. (NYSE:COR)

Catalina Capital Group LLC bought a new position in Cencora, Inc. (NYSE:COR) during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 955 shares of the company’s stock, valued at approximately $215,000.

A number of other hedge funds also recently made changes to their positions in the company. HF Advisory Group LLC increased its position in Cencora by 10.2% in the third quarter. HF Advisory Group LLC now owns 4,443 shares of the company’s stock worth $1,000,000 after purchasing an additional 412 shares during the last quarter. Amalgamated Bank increased its holdings in shares of Cencora by 6.2% in the 3rd quarter. Amalgamated Bank now owns 37,969 shares of the company’s stock worth $8,546,000 after buying an additional 2,228 shares during the last quarter. Moloney Securities Asset Management LLC raised its position in shares of Cencora by 11.7% during the 3rd quarter. Moloney Securities Asset Management LLC now owns 4,577 shares of the company’s stock valued at $1,030,000 after buying an additional 481 shares in the last quarter. Hazlett Burt & Watson Inc. lifted its holdings in shares of Cencora by 66.2% in the 3rd quarter. Hazlett Burt & Watson Inc. now owns 389 shares of the company’s stock valued at $88,000 after acquiring an additional 155 shares during the last quarter. Finally, PDS Planning Inc grew its position in Cencora by 17.2% in the third quarter. PDS Planning Inc now owns 1,247 shares of the company’s stock worth $281,000 after acquiring an additional 183 shares in the last quarter. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Cencora Price Performance

Shares of COR stock opened at $247.76 on Friday. The company has a market capitalization of $48.82 billion, a P/E ratio of 32.99, a P/E/G ratio of 1.49 and a beta of 0.44. The company’s 50-day simple moving average is $231.77 and its two-hundred day simple moving average is $230.76. Cencora, Inc. has a one year low of $191.11 and a one year high of $250.80. The company has a debt-to-equity ratio of 3.93, a current ratio of 0.89 and a quick ratio of 0.55.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $3.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.21 by $0.13. The company had revenue of $79.05 billion for the quarter, compared to analysts’ expectations of $77.68 billion. Cencora had a return on equity of 266.60% and a net margin of 0.65%. As a group, equities analysts anticipate that Cencora, Inc. will post 13.64 EPS for the current year.

Cencora Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, November 29th. Investors of record on Friday, November 15th will be issued a $0.55 dividend. This is an increase from Cencora’s previous quarterly dividend of $0.51. This represents a $2.20 annualized dividend and a dividend yield of 0.89%. The ex-dividend date is Friday, November 15th. Cencora’s payout ratio is presently 29.29%.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. UBS Group upped their price objective on Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a research report on Thursday. StockNews.com downgraded Cencora from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 20th. Evercore ISI boosted their price objective on shares of Cencora from $250.00 to $285.00 and gave the company an “outperform” rating in a research report on Thursday. Wells Fargo & Company increased their target price on shares of Cencora from $236.00 to $249.00 and gave the company an “equal weight” rating in a research note on Thursday, August 1st. Finally, Robert W. Baird upped their price target on shares of Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a report on Thursday. Three research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $271.20.

Insiders Place Their Bets

In other news, Chairman Steven H. Collis sold 21,509 shares of the business’s stock in a transaction dated Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total value of $5,071,822.20. Following the completion of the sale, the chairman now owns 285,088 shares in the company, valued at approximately $67,223,750.40. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 15.80% of the stock is owned by company insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.